Deciphera announces Health Canada’s authorisation of Qinlock (ripretinib) for the treatment of fourth-line gastro-intestinal stromal tumour

Deciphera Pharmaceuticals

22 June 2020 - Qinlock significantly improved progression-free survival and showed clinically meaningful overall survival in global INVICTUS Phase 3 study.

Deciphera Pharmaceuticals today announced that Health Canada has authorised Qinlock (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastro-intestinal stromal tumour who have received prior treatment with imatinib, sunitinib, and regorafenib. 

The Qinlock new drug submission was approved by Health Canada under Project Orbis, an initiative of the U.S. FDA Oncology Center of Excellence designed to provide a framework for concurrent submission and review of oncology products among international partners. 

Read Deciphera Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Canada